publication date: Apr. 10, 2015
MD Anderson Cancer Center President Ronald DePinho’s administration acted in disregard of academic standards and the institution’s internal faculty appointment policy, according to a 23-page final report published April 8 by the American Association of University Professors.
The report is the outcome of a yearlong feud between the cancer center and AAUP, which defends academic freedom and shared governance.
Nearly a year and a half after a surgical tool routinely used by gynecologists disseminated her undiagnosed sarcoma, Amy Reed found herself back in the operating room—this time for removal of a second metastasis.
Reed’s leiomyosarcoma, which had been in remission after a massive surgery and post-morcellation chemotherapy, has spread to her lumbar vertebrae.
False Positive Mammograms, Overdiagnosis Cost $4 Billion
The costs of false-positive mammograms and breast cancer overdiagnoses add up to $4 billion a year, according to a paper in the April edition of the journal Health Affairs.
The issue contains a cluster of papers focusing on the cost and quality of cancer care.
Draft Guideline on Colorectal Cancer Biomarker Published
The American Society for Clinical Pathology, the College of American Pathologists, the Association for Molecular Pathology, and the American Society of Clinical Oncology released a draft of a clinical practice guideline on the use of molecular marker testing for patients with primary or metastatic colorectal carcinoma.
This evidence-based guideline will help establish standard molecular marker testing, guide targeted therapies, and advance personalized care for these patients.
Karen Jensen joins Scripps Health as director of the oncology clinical care line
Chandini Portteus named president and CEO of LIVESTRONG Foundation
Margaret Hamburg, former FDA commissioner, appointed foreign secretary of IOM
The NCCN Foundation awarded fifth series of Young Investigator Awards to six oncology researchers
Christina Coughlin named chief medical officer of Immunocore Ltd.
Gerrit Los named vice president of pharmacology at AnaptysBio Inc.
Drugs and Targets
Vectibix gets European approval for wild-type RAS colon cancer
Intrexon Corp. signs cooperative research and development agreement with NCI
Rubicon Genomics Inc. extends its clinical supply agreement with Agendia
Merck and Pfizer will begin co-promoting Xalkori in eight countries